Clinical Trial Update: Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing neratinib plus paclitaxel to trastuzumab plus paclitaxel in ErbB-2 positive advanced breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)
• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-11-06